Abstract:Aims: Hearing loss is a common debilitating complication in nasopharyngeal carcinoma (NPC) survivors. The aim of the present study was to investigate the impact of inner ear/cochlear radiation dose and cisplatin use on early and late sensorineural hearing loss (SNHL) in NPC patients treated with radiotherapy alone, concurrent chemoradiation (cCRT) and induction chemotherapy followed by cCRT (iCRT) in the intensity-modulated radiotherapy era. Materials and methods: The study included 81 NPC patients treated with intensity-modulated radiotherapy between 2014 and 2016. Pure tone audiometry was carried out at baseline and follow-up. The effects of cochlear/inner ear radiation and cisplatin doses on early (<12 months) and late (≥24 months) SNHL were analysed using multivariable regression after adjusting for important predictors. Results: In total, 156 ears were examined. In early SNHL (n = 136), cisplatin use predicted the incidence of early high-frequency SHNL (HF-SNHL) (odds ratio 6.4, 95% confidence interval 1.7-23.9, P = 0.005). Ninety ears were analysed for late SNHL (median follow-up 38 months). Inner ear/cochlear radiation and cisplatin doses and better pre-treatment hearing were independent predictors of threshold change at 4 kHz. Every 10 Gy increase in inner ear/cochlear Dmean resulted in 5-dB and 6-dB threshold changes, respectively (cochlear Dmean: B = 0.005, 95% confidence interval 0.0004-0.009, P = 0.031; inner ear Dmean: B = 0.006, 95% confidence interval 0.001-0.010, P = 0.014). Cisplatin use was associated with late HF-SNHL (odds ratio 3.74, 95% confidence interval 1.1-12.3, P = 0.031). In the cCRT and iCRT subgroups, no cisplatin dose-dependent ototoxicity was observed. Severe (≥30 dB) late HF-SNHL occurred in 14% and 25% of the patients when the cochlear dose constraints were 40 Gy and 44 Gy, respectively. The radiotherapy-alone group did not develop severe late HF-SNHL. Conclusion: Cochlear/inner ear radiation dose and cisplatin use showed differential and independent ototoxicity in early and late SNHL. As cochlear/inner ear dose-dependent ototoxicity was demonstrated, the cochlear dose constraint should be as low as reasonably achievable, especially when cisplatin is also administered.

Radiation Therapy and Hearing Loss

Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children

Risk factors for treatment-related sensorineural hearing loss and hearing aid use in medulloblastoma patients: an observational cohort study

Hearing Loss After Cisplatin-based Chemoradiotherapy for Locally Advanced Head and Neck Cancer: A Prospective Single-institution Study

Optimizing Hearing Outcomes in Nasopharyngeal Cancer Survivors in the Era of Modern Radiotherapy and Systemic Therapy

Sensorineural Hearing Loss in Nasopharyngeal Carcinoma Survivors in the Modern Treatment Era - The Early and Late Effects of Radiation and Cisplatin

Tumors of the nervous system and hearing loss: beyond vestibular schwannomas

Dosimetric Parameters Associated with Conductive or Sensorineural Hearing Loss 5 Years after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma

Head and Neck Radiotherapy Causes Significant Disruptions of Cochlear Ribbon Synapses and Consequent Sensorineural Hearing Loss

Dosimetric analysis of hearing loss after cranial radiation therapy in children: A single-institution study from the french national registry pediart

The emerging role of hearing loss rehabilitation in patients with vestibular schwannoma treated with Gamma Knife radiosurgery: literature review

High doses of radiation cause cochlear immunological stress and sensorineural hearing loss

Current Understanding of Hearing Loss in Sporadic Vestibular Schwannomas: A Systematic Review

Prevailing Practices in Ototoxicity Monitoring in Individuals With Head and Neck Cancer Undergoing Radiotherapy and Chemoradiotherapy: A Scoping Review

Hearing loss during chemotherapy: prevalence, mechanisms, and protection

Cochlear Implantation After Radiotherapy of Vestibular Schwannomas

496 Impact of the Mean Cochlear Biologically Effective Dose on Hearing Preservation After Stereotactic Radiosurgery for Vestibular Schwannoma

The design and screening of drugs to prevent acquired sensorineural hearing loss

The relevance of ototoxicity induced by radiotherapy

Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer

Hearing preservation after stereotactic radiosurgery for sporadic intracanalicular vestibular schwannomas classified as Koos grade 1